EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company is headquartered in Watertown, Massachusetts.
| Revenue (TTM) | $2.79M |
| Gross Profit (TTM) | $-257.47M |
| EBITDA | $-314.38M |
| Operating Margin | -19207.00% |
| Return on Equity | -148.70% |
| Return on Assets | -74.90% |
| Revenue/Share (TTM) | $0.03 |
| Book Value | $0.40 |
| Price-to-Book | 2.11 |
| Price-to-Sales (TTM) | 108.86 |
| EV/Revenue | 57.41 |
| EV/EBITDA | 11.56 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -90.50% |
| Shares Outstanding | $86.21M |
| Float | $60.67M |
| % Insiders | 3.52% |
| % Institutions | 117.66% |
Volatility is currently expanding
NEW YORK, Sept. 24, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
WATERTOWN, Mass., Sept. 16, 2026 (GLOBE NEWSWIRE) -- EyePoint, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of patients with serious retinal diseases, today announced that the Company granted non-statutory stock options to new employee as inducement award outside the Company's 2023 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4).
NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. (“EyePoint” or the “Company”) (NASDAQ: EYPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
EyePoint, Inc. (EYPT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
RADNOR, Pa., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
NEW YORK, Sept. 10, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of EyePoint, Inc. ("EyePoint" or the "Company") (NASDAQ: EYPT).
EyePoint, Inc. (EYPT) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
RADNOR, Pa., Sept. 6, 2026 /PRNewswire/ -- Kessler Topaz Meltzer & Check, LLP (www.ktmc.com), a nationally recognized securities litigation law firm, is investigating potential violations of the federal securities laws by EyePoint, Inc. (NASDAQ: EYPT) on behalf of investors who purchased or acquired EyePoint, Inc. securities and experienced significant financial losses.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on EYPT and any ticker you trade — then tracks every position and per-strategy win rate.
